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ABSTRACT
Using Alzheimer’s disease as a case study, this review argues that it might be time to consider a new
paradigm in medical research and drug discovery. The existing framework is overly dependent on often
unvalidated animal models, particularly transgenic mice. Translational success remains elusive and costly
late-stage drug failure is common. The conventional paradigm tends to overlook species differences and
assumes that animal-based findings are generally applicable to humans. Could pathways-based research
using advanced human-specific models probed with new tools, including those of systems biology, take
centre stage? The current transition in chemical toxicology to a 21st-century paradigm could be a model
for health research, with probable medical and economic benefits.

Introduction
Total new drug approvals have continued to fall whereas the costs of producing novel medicines have
grown exponentially. Despite increasing investment, 92% of all novel drugs fail in clinical trials, mainly
because of unpredicted toxicity or insufficient efficacy in humans [1]. Problems in basic medical research,
drug discovery and effective translation from laboratory to clinic are widely recognised. Meanwhile, in
chemical toxicology a transformation is already unfolding, following a seminal report from the US National
Research Council in 2007 [2]. This recommended a ‘21st-century paradigm’ for safety testing, involving
an explicit transition away from a reliance on adverse endpoints in animal tests and towards a novel
framework based on understanding toxic perturbations to cellular pathways, mainly using in silico tools
and human-specific cell and tissue models. The National Research Council’s vision is being implemented
actively worldwide, including by the US multi-agency Tox21 consortium [3] and the Environmental
Protection Agency’s multi-million dollar ToxCast programme [4].
A recent refinement in toxicology is the concept of adverse outcome pathways (AOPs), which are
intended to provide clear mechanistic representations of critical toxic effects spanning molecular, cellular,
organ, individual and population levels. AOPs have a common structure comprising exposure to the first
molecular initiating event (e.g. a chemical binds to a cell receptor), intermediate steps and key events and
an adverse outcome that (in toxicology) could for example be cancer, allergy or liver damage. The first
validated AOP (for skin sensitisation) has now been accepted at the Organisation for Economic
Cooperation and Development and several further AOPs are in draft form [5].
The transition in toxicology could provide a template for modernising the disease modelling and drug
discovery paradigm. Developments in systems biology have enabled studies of human gene pathways
and networks linked to disease, and expanding this concept to an AOP approach would have obvious
relevance, widening consideration of disease pathways to include environmental factors at the start of the
pathway and whole-person or population-level outcomes at the pathway’s conclusion. Incorporating

advanced scientific tools into a research framework emphasising pathways and networks in humanspecific models could offer better progress towards understanding and treating diseases than the current
emphasis on animal models.
The animal model paradigm
For many decades, animal models have had key scientific and conceptual roles in health research and
drug discovery, because human experimentation was unethical and impractical and in vitro models were
simplistic and poorly representative of the in vivo situation. Within the traditional research paradigm,
animal models remain dominant and animal data are used in a ‘gate-keeper’ role [6] for studying
pathophysiological mechanisms, for probing novel therapeutic approaches and as preclinical models in
scientific guidelines [e.g. those of the International Conference on Harmonisation.
The animal model paradigm, although widely supported [7], has also been described as ‘seriously flawed’
and ‘not well suited’ for predicting human responses in clinical trials, where failure rates are very high [8].
Some authors refer to a ‘crisis of validation’ for animal models in neuroscience drug discovery, leading to
a high risk of developing mainly ‘me-too’ compounds [9]. Van Meer and colleagues describe the current
approach as ‘a stalemate in which animal studies, predictive or not, continue to exist with little room for
innovation’ [10]. They and others call for a critical assessment of the predictive value of animal studies,
from which it might emerge that new technologies can be implemented that predict efficacy as well as, or
better than, animal studies.
The regulatory requirement for preclinical animal data has been challenged, because much is of ‘unclear
relevance’ to human disease [11]. Tacit assumptions about the adequacy of rodent models in disease
research need to be questioned [12]; it is too often simply assumed that there are good correlations
between an accepted animal model and human subjects [13]. An analysis of 76 highly cited studies on a
range of animal species published in seven high-impact scientific journals found that only 37% accurately
predicted human outcomes [14].
Despite sustained investment in animal models, disease-modifying therapies remain elusive for major
illnesses such as Alzheimer’s disease (AD) [15], stroke [16], motor neuron disease [17], Huntington’s
disease [18], asthma [19], sepsis [20] and inflammatory diseases [6]. The animal-model paradigm tends
to discourage a critical appraisal of the differences between species and encourages a view that animalbased findings are generally applicable to humans [21]. However, evolutionary biology dictates that the
species barrier cannot be overcome and significant differences between animal models and human
diseases will continue to frustrate progress. For example, it is hard to envisage how animal models,
limited by inter- as well as intra-species variations, could expedite the development of more personalised
medicine.
Animal studies can provide useful in vivo data about selected pathologies, such as the amyloid pathway
in AD research, but increasingly this research could be conducted using novel human-and diseasespecific models and tools. These models and techniques are being incorporated into research in a
piecemeal manner but without a serious review of the long-standing gate-keeper role of animal studies. It
was the recognition that animal tests were inadequate and that advanced research tools were being
insufficiently exploited in chemical toxicology that led to the transition currently progressing in that field
[2].
With developments in systems biology, a systems understanding of human disease pathophysiology is
moving within our reach [1]. The coming together of a crisis of confidence in animal research with the

emergence of much better human in vitro models [22] and advanced techniques for human in vivo studies
creates a timely opportunity to review how a new paradigm could best incorporate these advances in a
coherent research framework. AD research is examined here as a case study of the limitations of the
present research framework, how a new vision for medical research might look and the potential benefits
it could achieve.
Alzheimer’s disease: translational failures
AD is a progressive dementia (Box 1) with classic pathologies comprising amyloid plaques in the brain,
neurofibrillary tangles (NFTs) containing abnormal tau and neuronal degeneration. Symptoms include
cognitive deficits, including memory disruption and impaired judgment, disorientation, confusion,
behavioural changes and difficulties moving, speaking and swallowing. Ultimately fatal, AD causes
suffering to patients and their families over a long period of time. The prevalence of AD worldwide is
expected to triple over the next 40 years, so the need for progress is very pressing.
The five approved drugs for AD can stabilise symptoms temporarily, but do not slow disease progression.
Around half of patients benefit modestly [23], but there is an urgent need for better, disease-modifying
therapies as well as preventative measures. The link between cholinergic deficits and AD, first discovered
through analysis of post-mortem human brain tissue in the 1970s and 1980s and then pursued with
animal studies, led to the four existing cholinesterase inhibitor drugs. Since the approval of memantine (a
glutamate receptor blocker) a decade ago, many novel compounds for AD have entered clinical trials, but
so far none has successfully completed a Phase III trial despite encouraging preclinical results in
transgenic (Tg) mice (Table 1).
There are many acknowledged reasons for failures of translational research [24]. Although numerous
improvements can be made to the methodology of animal studies, including for AD [15], they remain
inevitably flawed by: the ‘insuperable species barrier’ [13], comprising fundamental under-lying species
differences between animals and humans; the dis-parities between animal models and human diseases
in complexity, causation, pathophysiology and progression; the uncertain relevance to humans of the
results of behavioural studies in animals [25].
The limitations of mouse models in AD research
Some AD research is conducted in dogs, primates, ageing rats and chemical- and lesion-induced
rodents, and newer models include genetically modified zebrafish and the nematode worm
Caenorhabditis elegans. However, by far the dominant animal models over the past 15 years have been
Tg mice. Most of the Tg mouse lines are based on one or several inserted human genes relevant to the
amyloid hypothesis of AD causation [7,26].
The reliability of a model is considered in terms of its validity (summarised in Box 3) [27]. Regarding face
validity, some lines of Tg mice develop plaques and/or NFTs, a few show some neuronal loss and some
have cognitive deficits. However, the disease dynamics differ, none of the models fully recapitulates AD
and the phenotypic similarities are species-andstrain-dependent. In the case of construct validity,
although sporadic AD (sAD) is dominant in humans, Tg mouse genotypes resemble the much rarer (~5%
of cases in humans) familial AD (fAD). In humans, fAD is linked to mutations in the amyloid precursor
protein (APP), presenilin 1 and presenilin 2 genes, none of which singly or combined leads to a full
spectrum of AD pathologies in mice. None of the Tg mouse lines overexpressing APP ‘by any stretch of
the imagination’ develops cognitive or behavioural deficits approaching those typical of AD [7]. Some Tg
mice expressing human tau variants have a fuller pathology, but in humans these tau variants are not

associated with any form of AD. Triply Tg mice, generated using presenilin 1 knockin mice and microinjecting APP and FTDP-17 (a tau mutation) transgenes, develop amyloid plaques, NFT-type lesions and
deficits in spatial memory; but they reflect a composite of two distinct diseases neither of which is AD.
Few AD cell pathways are known and those studied in Tg mice, such as amyloid deposition, are
considered to have generated useful mechanistic data but are limiting in terms of novel drug targets and
have been poorly predictive of clinical outcomes. The development of Tg mice for model human disease
pathways can only be attempted once a pathway is known to be significant in patients. Emerging humanand disease-specific models potentially offer a way out of this stalemate by enabling the discovery and
detailed study of new human pathways and drug targets.
In translational science predictive validity is crucial. Studies of Tg mice have certainly contributed to an
understanding of some AD pathways and more than 300 interventions have been tested as a result;
however, as discussed above, none has translated into disease-modifying therapies [7,15]. Models that
meet more levels of validity are clearly of higher utility and relevance than those where validity is weaker.
Most animal models, including those for AD, do not fulfil sufficient validity measures and the conclusions
that can be drawn from their use should be more strongly qualified [13].
Many animal models have never been evaluated systematically, for example by systematic review and
meta-analysis of performance characteristics such as reproducibility, specificity, sensitivity, clinical
relevance or mechanistic basis [28]. At the time of writing, no systematic reviews have been published
about the predictive ability of Tg mouse models of AD. This is in stark contrast to recommendations that
systematic reviews of the clinical relevance and the risk of bias of preclinical research should be
conducted before the start of clinical trials [29,30]. Without systematic evidence of validity, the utility of
animal models including Tg mice in AD research is unproven; and yet costly clinical trials, of potential risk
to participants, are conducted primarily on the basis of these data.
The species barrier is a highly significant problem in developing valid models of human diseases. Mouse
models seldom sufficiently recapitulate human disease pathways and pathologies, including in AD,
because of important underlying species differences in genetics, protein pathways, metabolism,
pharmacology and physiology that have accumulated since rodents and humans diverged 65–85 million
years ago. Evolutionary divergence in protein functions and gene regulatory networks can complicate
studies in animals, and it should not be assumed that gene function is conserved between animals and
humans until functional equivalence is demonstrated [31]. In considering AD, unlike humans mice are
naturally resistant to age-related amyloid pathology. Mouse and human APPs differ by 17 amino acids –
three in the amyloid-b peptide (Ab) sequence. Knockin mice with APP mutations express humanised Ab
but do not develop amyloid plaques or neuropathology [26], implicating fundamental differences such as
a shorter lifespan or dissimilar processing of mouse APP by b-secretase. Mouse brain only has 4R tau,
whereas human brain has 3R and 4R tau isoforms that are both hyperphosphorylated in AD. There are
14 amino acid differences in the N-terminal region of human and murine tau, and the difficulties in
inducing NFTs in mice could be attributable to these disparities [26].
Only humans have genetic variants of the apolipoprotein E gene (APOE), a major gene associated with
sAD. Human APOE*e4 has a unique domain interaction between the Arg61 and Glu255 residues,
responsible for most of its associated neuropathology. The one murine APOE has Thr61 instead of
Arg61, preventing the APOE*e4 domain interaction. Researching the role of APOE*e4 in mice has
necessitated the generation of complex Tg lines, possibly introducing confounding issues. Presenilin 1
correlates highly with oligodendrocyte markers only in humans, not in mice [32]. The human presenilin 2

promoters are modulated differently from the murine equivalent, and presenilin mutations produce almost
no plaque pathology in Tg mice.
A major known risk factor of sAD is ageing. Humans experience a dramatic increase in age-dependent
repression of broad-spectrum neuronal genes compared with mice, likely to alter neural networks and
result in cognitive changes. Adult neurogenesis occurs significantly in the rodent hippocampus but is
much less obvious (or absent) in longer-lived species, including humans [33]. Of 49 well-known genes
examined in the mouse cortex and hippocampus, over 50% showed inter-strain expression variation, with
probable consequences for behaviour and drug responses [34]. Neuronal nitric oxide synthase is
prominently expressed in C57B6 mice but its levels are much lower in SV129 mice. Fundamental strainand species-dependent variations such as these cause difficulties in extrapolation from rodent data to
humans. In different species, functionally equivalent receptors can have distinctive pharmacological
profiles. Currently, drug candidates are frequently optimised for rodent pharmacology and the first time a
novel drug is challenged by a range of human pharmacologies is often at the clinical trial stage, when
failure is very costly.
In Tg mice, connections between the increase in Ab, lesions and symptoms have resisted clarification.
Many mice show behavioural changes before significant plaque deposition – the reverse of the human
situation. The relative abundance of Ab peptides in APP23 mice and AD patients differs, suggesting
dissimilar mechanisms underlying amyloid deposition. In AD brains the unfolded protein response is
upregulated; but in Tg2576 mice neither the unfolded protein response nor the cell-death pathway is
induced [35]. There are also species variations in post-translational modifications of amyloid peptides and
their resistance to degradation, thought to be related to differences in lifespan and physiology between
mice and humans.
One of the strengths of in vivo models of AD, and a contributing feature of their construct and predictive
validities, should be the opportunity to measure relevant behavioural indicators of cognitive deficits. Tg
mouse models are sometimes defended as essential because learning and memory deficits are core to
AD and cannot be replicated in conventional in vitro models. But functional studies with Tg mice are not
predictive and it is not known how, if at all, behavioural tests reflect AD cognitive deficits [26]. Philipson et
al. point out that behavioural studies with Tg mice can be relevant to understanding whether an amyloid
species or a pathology has a functional effect on neurotransmission but are inadequate for predicting
whether a drug alters AD symptoms [36].
Functional studies in mice are also poorly reproducible, between and even within laboratories, and test
performance is influenced by the selected promoter gene, by transgene overexpression and by the choice
of background strain [37]. Some strains are notably aggressive, neophobic or anxious which confounds
interpretation of aspects of cognitive performance, and some perform particularly badly in the Morris
water maze test of spatial memory [38]. In the mid-1990s, Tg2576 mice were reported to have a memory
deficit that correlated with amyloid plaques, but this was challenged [39] and the argument was still
rumbling on nine years later. Dramatically different phenotypes can arise from using the same mutations
and promoters, and Tg mouse lines are subject to sensorimotor and cognitive impairments that do not
replicate AD [40]. Cognitive deficiencies in Tg mice are not only age-dependent but also task- and
sometimes gender-dependent, making extrapolation to humans very difficult.
Under the current research paradigm, the mainstream opinion is that animal models remain necessary
and should be improved [9,13,15,36]. For example, it has been argued that disease end-points other than
massive Ab deposits could be used in rodents and might have more translational relevance. Olfactory
dysfunction, an early symptom in AD, could provide a marker of disease progression and drug effect in Tg

mice [41]. Such developments could yield improved predictive validity over existing Tg mouse models, but
further research and validation will take time and the poor face and construct validities of mouse models,
as well as the species barrier, would remain unaddressed. With the emergence of 21st-century humanspecific models and tools, positioning human rather than animal pathophysiology at the centre of
research efforts might be more productive [6].
Advances in human cell models and tools
Until recently, research and drug discovery in AD (as in other fields) have been hampered not only by
animal models of limited utility and unproven validity but also by overly simplistic human cellular models.
The standard cell models have often used cancer cell lines with many genetic changes in static,
monolayer culture, which fails to replicate the architecture, cellular interactions, differentiation status and
functionality of human tissue [42].
But this century has seen new advances in human cell models and applicable tools, which are expected
substantially to increase the value and relevance of human cell-based research. Human induced
pluripotent stem cells (hiPSC), generated by reprogramming adult human cells and differentiated in vitro,
provide significant opportunities for generating unique disease-relevant, tissue- and human-specific cell
models, even in genetically complex diseases such as sAD. hiPSC generated from patients with fAD and
sAD have been differentiated into functional and electrophysiologically active neurons [43] with increased
Ab1–40, active glycogen synthase kinase-3b and phosphorylated tau. In another study, Ab peptides
accumulated in neurons and astrocytes derived from hiPSC from fAD and sAD patients, leading to
endoplasmic reticulum and oxidative stress. The research further demonstrated the usefulness of patientspecific hiPSC in probing AD pathogenesis and evaluating drugs [44]. Thus, hiPSC studies are expected
to provide novel insights into pathways of AD initiation and pathogenesis, the roles of different cell types,
drug screening and development studies, patient-specific drug responses, prospective diagnostics [45]
and the role of sAD susceptibility genes identified in genome-wide association studies (GWAS). hiPSC
derived from individuals with genetic variations of interest and differentiated into neural cells can now be
deep-sequenced using high-through-put, automated technology. The combined availability of patient-and
disease-specific genetic material and living in vitro models could help achieve the ultimate goal of relating
genotype and phenotype, for example correlating individual genetic variants with gene expression
patterns, cellular disease pathways and altered functions of neural cells [46].
Another adult human source of pluripotent stem cells is the olfactory mucosa, which is easily biopsied or
sampled postmortem. Post-mortem olfactory stem cells from individuals with Alzheimer’s disease showed
differences in APP processing and oxidative stress, and in vitro models of neurological diseases based
on biopsied human olfactory stem cells offer several practical advantages over hiPSC for drug discovery
[47].
So that human stem-cell-derived models can achieve their full research potential, optimisation of
reprogramming techniques for somatic cells, identifying markers that predict differentiation potential,
improving in vitro differentiation protocols and generating purer cell populations are some of the
challenges that must be overcome [42]. Where post-mortem tissue from the same patient is available,
detailed findings in hiPSC-derived cells in vitro can be directly validated. Acknowledging that animal
disease models are time-consuming, costly and predict drug efficacy in humans imperfectly, the US
National Institutes of Health (NIH) envisages that better target validation using human tissues and hiPSC
could eliminate testing for drug efficacy in animals altogether [48]. Grskovic and colleagues also foresee
hiPSC technology providing a new, human-disease-based drug discovery paradigm, in which older
models (including ‘nonpredictive animal models’ and simplistic cell cultures) are replaced, leading to

human efficacy and toxicity data being available earlier and even moving directly ‘from in vitro clinical
trials to actual clinical trials’ [49].
In vitro clinical trials would provide human efficacy (and toxicity) information at multiple dose levels and
data on the heterogeneity of the patient population, minimising risks of later failures and achieving faster
timeframes with lower-cost, high-throughput biological platforms [49]. A clearer understanding of
genotype– phenotype relationships in disease-specific human cells is also on the horizon, potentially
providing a crucial link between basic research and translation. Patient-derived hiPSC models should be
able to identify hits that alter the disease phenotype, as well as having promise for target validation, lead
optimisation, candidate selection, biomarker discovery and personalised medicine [50].
Tissue engineering creates robust and controllable 3D in vitro human tissue models that better replicate
the in vivo spatial environment. Compared with 2D cultures, tissue engineered models have improved
viability and many cellular and tissue processes are closer to the in vivo situation. The production and
function of these tissue constructs can be tightly controlled with fewer confounding factors than when
using living animals, and they are expected to have promising applications in disease modelling and
toxicology [51].
Microfluidics technology employs microchip devices incorporating a laminar flow of culture medium,
improving the transport of nutrients and waste products. They offer rapid, reproducible and sensitive
platforms compatible with high-throughput processing or high-content analysis. Organ-on-a-chip devices
combine microfluidics with 3D culture, aiming to reproduce key structural, functional and biochemical
features of human organs in vitro. Human lung and gut are two of several models available, with brain-ona-chip systems currently under development [22]. These technologies are another key tool to create highquality, high-throughput in vitro models for better testing of drug efficacy and toxicity, and potentially for
studying disease pathways and identifying new drug targets in human-relevant systems [22,52]. The NIH
anticipates that they have ‘the potential to change paradigms of how we develop therapies, inform
regulatory decision-making process and shorten clinical trials’ (http://www.ncats.nih.gov/about/faq/tissuechip/tis- sue-chip.html). There have also been developments in electrophysiological techniques applicable
to human cells in vitro, providing key functional data. Automated patch-clamping combined with
microfluidic channels now yields sensitive, high-quality, high- throughput data including measurements of
very fast ligand-gated ion channels and receptors in cell lines [53].
In AD research, studies of deficits in learning and memory have classically relied on mouse models [9]
and in vitro alternatives are not yet validated. However, if human neural networks can be studied reliably
in vitro, they could overcome a key challenge: assessing drug effects on aspects of learning and memory.
A reliable tool for functional studies would improve translational success, because rodent models are
poorly reproducible [37], time-consuming [36] and of unknown relevance [25]. Microelectrode array
devices populated in vitro with human-stem-cell-derived neuronal cells allowed functional studies of
spontaneous network activity and neuronal receptor responses over several weeks and studies of
mechanisms underlying learning and memory [54]. Optogenetic techniques combined with multielectrode
arrays applied to cultured neuronal networks enable studies of short-term memory mechanisms in vitro,
and should provide a rapid screening tool for drugs [55]. Human cortical development to the level of
functional synapses and networks has recently been achieved in vitro using hiPSC, opening the door to
novel functional models resembling the in vivo cortex in circuit specificity and laminar organisation of
cortical projection neurons [56]. These emerging human models certainly need further investment.

The wide range of emerging human-specific cellular models and ‘next-generation’ tools with which to
probe them are undergoing rapid development and validation. If their potential is realised they will
become game-changers for disease research and drug discovery.
Human tissue and omics analyses
Human post-mortem tissue research into AD has declined since it led to the discovery of the
cholinesterase-inhibitor drugs, but that will change as better quality specimens become available and
next-generation sequencing enables a rapid and unbiased characterisation of messenger RNA, proteins
and metabolites associated with disease. New transcriptomics analyses needing no a priori etiological
hypotheses will advance understanding of AD pathogenesis. In 2013, an elegant study integrated publicly
available data from GWAS with that from human cortical transcriptional networks and human
neuroimaging, to advance knowledge of key regulatory molecules and pathways involved in APOErelated risk of AD [57]. Laser-capture microdissection enables gene expression profiling of selected
cortical neurons from post-mortem brain, and has revealed significant differential expression of ADimplicated genes in regions of AD brains compared with controls. In the epigenetics field, research is
underway to elucidate specific genes affected by epigenetic changes and whether these implicate
proteins and pathological processes relevant to AD [58].
Human pathology can also be probed by analysing cerebrospinal fluid (CSF) or blood samples from
subjects at different disease stages, and linked with neuroimaging and magnetic resonance spectroscopy
data. Current diagnostic guidelines for AD include three CSF biomarkers [59] and these human in vivo
data are of potentially high value to understanding AD pathology, following disease progression and
developing new drugs [59].
Quantitative proteomics offers comprehensive insights into disease phenotypes and pathways and
advanced analytical techniques have dramatically improved in speed and precision. An analysis of
cortical samples of AD and normal brains using high- resolution mass spectrometry [60] recently identified
and quantified 197 proteins of significantly different abundance in AD brain samples. Mapping with
bioinformatics tools revealed associations with multiple pathways and processes important in AD. Protein
identification with capillary electrophoresis coupled to an electrospray ionisation time-of-flight mass
spectrometer was used recently with AD brain tissue to reveal abnormal phosphorylation in nine proteins
that influence cell metabolism, signal transduction, cytoskeleton integration and synaptic function [61].
Advanced human in vivo studies
Neuroimaging is one expanding approach to human in vivo research in AD and other neurological
disorders. Imaging technologies are advancing rapidly in specificity and sensitivity, in spatial and temporal
resolution, and in automated image analysis, impacting progress in elucidating pathways of human
disease, early diagnosis, patient stratification, personalised therapies and treatment evaluation, including
effects on cognitive dysfunction. Safe human in vivo studies are a key component of a new research
paradigm, also providing a species-relevant link that helps inform and validate in vitro techniques.
Ultra-high-field magnetic resonance imaging (MRI) can now directly visualise cortical plaque disposition
and early tissue loss in the hippocampus of patients previously only visible in postmortem tissue [62].
Multimodal magnetic resonance tools can measure and correlate structural, functional, metabolic and
haemodynamic changes in the brain and have been used in several studies of AD. Magnetic resonance
spectroscopy detects and quantifies in vivo metabolites that reflect the status of neuronal and glial cells,
energy metabolism, inflammation and neurotransmitters. Improvements in sensitivity are expected to lead

to progress in real-time monitoring of in vivo metabolic processes in the human brain. Diffusion tensor
imaging traces neural tracts and micro-structural damage in white matter in the human brain that can be
correlated with omics, pathogenesis, disease progression and cognitive features of AD.
Positron emission tomography (PET) studies in patients have revealed new information about plaque
distribution and some clinical trials have exploited Ab as a biomarker. In 2013, a new tau ligand was
developed that enables sensitive PET imaging of tau NFTs in living patients with AD for the first time [63].
This development offers exciting possibilities for earlier AD diagnoses, better stratification of patients in
clinical trials, a new marker for treatment effect and insights into the pathophysiology and progression of
AD in human patients.
Human connectomics is a scientific concept emerging in response to imaging advances. The Human
Connectome Project (http://www.humanconnectomeproject.org) aims to combine imaging data from
hundreds of participants to create a comprehensive circuitry map of the human brain and to link this to
genetics and behaviour. Connectome studies of AD have already demonstrated abnormal functional
connectivity between and within hemispheres. A recent genome-wide analysis of the connectome
involved 366 twins scanned with MRI and high- angular resolution diffusion imaging to trace fibre tracts
through the whole brain [64]. Significant associations between gene variants and connectivity were found
in some fibre tracts, and the study was also important in indicating the relative contributions of genetic
and environmental factors to brain connectivity.
Genome-wide association studies
Genome-wide association studies enable the automated analysis of the entire genome. Sequencing costs
have plummeted by orders of magnitude during the past ten years, whereas levels of accuracy have
increased. Common single nucleotide polymorphisms and other DNA variants significantly associated
with disease can be identified. For example, nine genes newly associated with sAD through GWAS were
mapped onto pathways linked to immune function, cholesterol metabolism and synaptic membrane
processes, offering new angles for research and therapeutic intervention [65]. As susceptibility genes are
catalogued and pathways are increasingly clustered, convergent nodes will be identified that could
provide targets for new treatments.
The characterisation and reconstruction of molecular interactions related to GWAS-discovered genes for
five complex disorders, including AD, suggested that susceptibilities converge on com-mon molecular and
biological networks [66]. In AD, unexpected significant relationships between immune function and growth
factor signalling pathways were found. Other approaches are being developed to look for rarer novel
variants and mutations, such as a pooled-DNA technique with next-generation, high-throughput
sequencing and bioinformatics analyses, which found variants in APP and presenilins 1 and 2 that cause
or increase the risk of sAD [67]. The deCODE Iceland study identified a low-frequency coding mutation in
the APP gene that protects against AD, the first protective sequence variant found [68].
In contrast to genetics, the tools used to discover environmental influences in disease have hardly
progressed since the mid 20th century. A new concept to address this is the exposome, envisaged as the
totality of a person’s environmental exposures that can be characterised in an unbiased way by
measuring all the external exposures (e.g. chemicals, drugs, radiation, infection, stress) that create
internal toxins (e.g. produced by inflammation, oxidative stress, lipid peroxidation) in biological fluids,
such as blood samples taken at different time points [69]. Exposome research could explore these
nongenetic influences in AD, identifying early steps in an AOP for AD.

Systems biology and computational modelling
Computational interpretation, integration and modelling of different levels of human experimental data-molecular, cellular, tissue, organ, clinical and population--is a rapidly progressing approach for
understanding complex, nonlinear biological processes. Current research emphasises the discovery of
single drug targets for which highly selective ligands are designed. But this strategy might be inadequate
when the pathology is complex, as in AD. Many effective drugs act through effects on multiple proteins;
systems biology research recognises a dynamic network of cellular pathways that could provide multiple
targets for treatment [70].
A systems biology approach is essential for making sense of the data explosion resulting from omics
studies, and can give a clearer understanding of cellular disease pathways and progression, as well as
helping to identify sensitive and early biomarkers of drug efficacy. The complexity of human illnesses-such as cancer, cardiovascular disease and AD--demands a systems-based under-standing, as does the
integration of human molecular, cellular, physiological and environmental data to extend the concept of
cellular pathways to the elucidation of disease AOPs (Fig. 1).
The NIH proposes developing quantitative and systems pharmacology (QSP) to advance drug discovery
and development by exploiting new knowledge of human cellular and tissue networks [71]. Using QSP to
combine computational and experimental methods at multiple scales from biochemistry through to
population levels is expected to result in less attrition in drug development, the discovery of new uses of
existing drugs and novel tools for translating cell-level discoveries to tissues and to patients.
The development of small computational models of protein signalling pathways for major diseases,
including AD, has shown that small-module systems analysis can be performed rapidly to generate new
ideas to guide experimental research and to suggest new therapeutic concepts [72], whereas Tg mouse
research is costly, time-consuming and oriented to single targets. AlzPathway, a publicly available map of
signalling pathways, will help to evaluate candidate risk genes identified by GWAS and to analyse omics
data [73].
Combining pathway analysis of GWAS data with composite memory scores in patients has highlighted
pathways associated with memory impairment, demonstrating the potential of this technique to elucidate
key targets in humans [74]. This study also thereby provided information for starting to build an AOP for
AD. Bioinformatic analysis of networks identified by global gene expression profiling in AD brains is
generating data about cell-level events in AD pathogenesis. Differential co-expression correlation network
analysis of APOE*e4 and AD transcriptomic changes recently identified candidate core regulatory
mediators related to sAD, and a gene variant that significantly affected amyloid deposition in human brain
and AD age of onset of sAD. The results suggest a molecular pathway associated with APOE*e4 that
promotes sAD [57].
Novel technologies are being developed for large-scale screening of protein–protein interactions and for
following specific interactions in depth. In 2012, a transcriptional atlas of the adult human brain was
generated, combining extensive histology and microarray profiling of about 900 brain areas, based on an
analysis of the Allen Human Brain Atlas [75]. Anatomically precise, genomewide maps of transcription
patterns complement genomic sequence data and will help correlations of functional and genetic brain
architecture.
Recently, data from diffusion tensor imaging and whole-brain microarray gene expression from a single
individual have been analysed to identify connectivity between the hippocampi and the rest of the brain,

as well as protein–protein interactions of relevance to AD in the same fibre tracts [76]. This showed that
protein–protein interaction data can be related to measurable fibre tract deterioration in AD brains. Large,
collaborative, longitudinal studies combining data from multiple technologies such as MRI, PET, CSF and
blood biomarkers, genetics and neuropsychology are invaluable for understanding structural and
functional connectivity and cognitive outcomes in AD research [77]. Systems biology developments
provide, for the first time, a way to make sense of complex systems, such as AD and brain circuitry, with
their nonlinear dynamics, multiscale organisation and emergent properties.
Concluding remarks
Animal studies remain dominant in the current paradigm for health research and drug discovery, yet
costly and significant translational failures are acknowledged to be unsustainable. In AD research, the
focus on Tg mice continues despite their incomplete pathophysiology and unrepresentative etiologies,
and a notable lack of evidence for their construct and predictive validity. If animal models are insufficiently
predictive then disease and drug discovery research pursued within the traditional framework, with animal
data playing a key part, will continue to disappoint. With the inevitable limitations of species variations, the
quest for better animal models begins to seem outdated when a suite of advanced techniques could be
applied to reliable human-specific models.
In toxicology, a structured and deliberate paradigm change is underway, moving away from animal testing
and apical endpoints of toxicity towards a framework built more on advanced in vitro and in silico methods
with a focus on human biology and AOPs. Thus, key aspects of the toxicology transition are the
structured implementation of next-generation techniques and the shared understanding that animal use
will decline, because better science is needed to make faster progress.
This review proposes that a similar change in conceptual think-ing and research practice would benefit
health research, argued here in the case of AD. Health research has an advantage over toxicology
because the ‘gold standard’ human model is available with the technologies to use it. As discussed in this
review, data from human in vivo and modern in vitro models, integrated and interpreted using systems
biology and computer modelling, will elucidate human disease AOPs that link causes and effects from
external factors through cellular changes to individual and population outcomes. This will help to create
the systems-based under-standing of complex diseases that so far has remained elusive, and which
provides a core aspect of a new research paradigm.
A modern framework for disease modelling and drug discovery that rationally integrates important new
and emerging techniques needs to be considered now. In-depth analyses of the limitations and
advantages of animal models and of next-generation human-biology-based in vitro, in silico and in vivo
methods could point to research funding and effort being directed away from efforts to improve animal
models and towards the further development of non-animal methods. As in toxicology, the expectation
would be for more cost-effective and more predictive data (than currently provided by conventional in vitro
and animal studies), by reducing reliance on Tg mice, providing earlier human-relevant information and
minimising late-stage drug attrition.
Considering change in a major paradigm of medical research is certainly a daunting task, but the
probable advantages are substantial. For decades animal models have been seen as core to health
research, but therapeutic progress has been slow, increasingly disappointing and costly. Emerging
models and tools need further development and validation, but serious discussion and planning of a new
framework for basic medical research and drug discovery should start now.
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Box 1
Classic pathologies of Alzheimer’s disease (AD)
Underlying the progressive cognitive deficits of AD are three classic pathologies: extracellular plaques
containing amyloid peptides; intracellular neurofibrillary tangles (NFTs); and neuronal degeneration
including synaptic loss.
Amyloid plaques occur mainly in the cerebral cortex and in the hippocampus, regions of the brain
associated with higher cognition and memory function. The plaque cores are formed from abnormally
folded amyloid-b (Ab) peptides, generated from the proteolytic actions of b- and g-secretases on the
larger amyloid precursor protein (APP). Presenilins form part of the g-secretase complex which, together
with b-secretase, cleaves APP.
According to the amyloid cascade hypothesis, APP processing is abnormally shifted towards Ab
production. This leads to increased amounts of Ab39–42 aggregating into insoluble plaque-forming fibrils
that disrupt neural function. Amyloid plaques often appear many years before people develop symptoms
of AD and amyloid burden alone poorly predicts cognitive function.
Intracellular NFTs comprise hyperphosphorylated and abnormally aggregated forms of tau protein.
Normal tau promotes the assembly and stability of neuronal microtubules but when hyperphosphorylated
it aggregates into NFTs in neurons, leading to cell death. The deposition of tau aggregates correlates
spatially and temporally with the development of dementia in AD. However, despite the obvious
significance of tau in AD, no tau mutations have yet been associated with the human disease.
Synaptic and neuronal degeneration comprise the third characteristic pathology of AD. Changes in
synaptic density correlate strongly with decline in cognitive ability. The neurons of the hippocampus and
the association areas involved in all other cognitive functions become increasingly dysfunctional, with loss
of dendritic spines and synapses. Neurotransmitter pathways start to fail, notably but not only the
cholinergic system. Progressive brain atrophy, particularly in the neocortex and hippocampus, is
observable in structural magnetic resonance imaging (MRI) scans.

Box 2
Common reasons for failures of translational research







Methodological flaws and poor design in preclinical studies, leading first to systematic bias and
then to inadequate data and incorrect views of efficacy.
Critical disparities between humans and animals (and also within animal species), including
pathophysiological differences, which result in unreliable outcomes.
Disparities between animal studies and clinical trials (e.g. in co-morbidities, the use of comedication, the stage of disease, the timing and dosing of the test treatment, and selection of
outcome measures).
Insufficient reporting of details of animals, materials and methods.
Publication bias, which could account for a substantial part of the efficacy reported in the
experimental literature for various diseases.

Box 3
Considering the validity of a human disease model
An established framework posits three types of validators: face, construct and predictive validity. Face
validity addresses phenomenological similarities between a model and a human disease. Although useful
in the development of a new model, face validity is less suitable for validating a model, because
superficial similarities do not always have the same underlying mechanisms or pathways. Construct
validity addresses the theoretical rationale, asking whether the model reflects the etiology and underlying
mechanisms or pathways of the human disease, and if the outcome measures match the clinical setting.
Predictive validity asks whether a model accurately predicts what happens in humans, especially the
effects of therapeutic interventions. It is a key factor in translational science.

Figure 1: Likely information sources and data outputs in a new research paradigm using human-specific models to
understand disease pathways. Data from 21st-century human in vivo and in vitro models, integrated and interpreted
using systems biology and computer modelling, could help elucidate human disease AOPs (linking causes and
effects for human diseases) from external factors through cellular changes to individual and population outcomes.
This will help to create a systems-based understanding of complex diseases that so far has remained elusive. Black
arrows indicate information sources, red arrows indicate data outputs. Abbreviations: AOPs, adverse outcome
pathways; GWAS, genome-wide association studies; hiPSC, human induced pluripotent stem cells; omics, group
including genomics, transcriptomics, proteomics and epigenomics.

Table 1: Results from Tg mouse studies compared with recent Alzheimer’s disease (AD) clinical trial outcomes
Generic drug name
(trademark name)
and company

Proposed
mechanism of
action

Preclinical Tg mouse
results

Clinical trial results

Refs

AN1792 Elan

Aβ1–42peptide,
active
immunotherapy
targeting amyloid
pathway.

Generated anti-Aβ
antibodies that reduced
plaques, neuritic dystrophy
and astrogliosis in older
PDAPP mice and prevented
these pathologies in younger
animals. No
meningoencephalitis.

Phase II, terminated 2002: removed plaque but failed to
affect cognitive decline. No improved survival or time to
severe dementia. Several patients developed autoimmune
meningoencephalitis.

[78,79]

Tramiprosate
TM
(Alzhemed ),
Neurochem

An amino acid that
binds to Aβ
monomers to
prevent plaque
formation.

In TgCRND8 mice reduced
brain amyloid plaque by 30%
and reduced plasma Aβ
levels.

Phase III: no cognitive improvement, no significant
treatment effect seen. Withdrawn from development.

[80,81]

Tarenflurbil
TM
(Flurizan ), Myriad

Gamma-secretase
modulator intended
to reduce Aβ.

Phase III: did not slow cognitive decline or delay loss of
normal daily activities. Discontinued for AD indications.

[82,83]

Semagacestat , Eli
Lilly

Gamma-secretase
inhibitor, intended to
reduce production
of Aβ plaques.

Long-term Phase III: failure to slow disease progression
and did not improve cognitive status. Patients on higher
dose had significant worsening of functional ability. Trial
stopped 2010.

[84,85]

Tideglusib , Noscira

Inhibitor of glycogen
synthase kinase- 3,
intended to reduce
tau hyperphosphory
lation.

Phase II, 2012: company announced that primary
cognitive end point and two of the secondary endpoints
were not met
(http://zeltia.com/actualidad.cfm?anyo=2012&semestre=2)

[86]

Rosiglitazone
(Avandia®),
GlaxoSmithKline

Antidiabetic drug
that activates
peroxisome
proliferatoractivated receptors.

Phase II: modest cognitive improvement in non-APOE*e4
subjects but decline in APOE*e4 patients.

[87,88]

Atorvastatin
(Lipitor®), Pfizer

Statin targeting
amyloid pathway.

Bapineuzumab ,
Pfizer and Janssen
AI

Humanised
monoclonal
antibody: passive
immunotherapy
intended to bind
and clear Aβ.

Attenuated spatial learning
deficits if given early in
Tg2576 mice .Older Tg2576
mice had significant
decrease in plaques.
Reduced plaques and
lowered Aβ in plasma, CSF
and brain in a dosedependent manner in
PDAPP Tg mice.
In Tg mouse models, it
reduced lesions including Aβ
and tau deposits, gliosis and
neuronal loss, and
significantly improved
behavioural impairments.
Reduced Aβ1–42 levels
without affecting amyloid
deposition, and improved
spatial learning and memory
function in Tg2576 mice.
Markedly attenuated brain
Aβ deposition in PSAPP
doubly Tg mice.
An anti-Aβ monoclonal
antibody (3D6) substantially
prevented and/or reduced
amyloid deposits in cerebral
vasculature in PDAPP mice.

Solanezumab , Eli
Lilly

Humanised
monoclonal
antibody: passive
immunotherapy
intended to bind
and clear soluble
Aβ.

Acute and subchronic
treatment of Tg mice
attenuated or reversed
memory deficits.

Latrepirdine
(Dimebon), Pfizer
and Med ivation

Oral antihistamine
with proposed but
unproven effect on
mitochondria.

Treated TgCRND8 mice
showed improved learning
behavior and less
accumulation of Aβ1–42 and
α-synuclein (conducted after
clinical trial).

Phase III: no significant cognitive efficacy at any dose, in
any test group. Trials discontinued.
Large scale randomised controlled trial for mild-tomoderate AD: no benefit to cognition or global function
compared with placebo.
Phase II: weak to nonexistent clinical benefits on
cognition. High doses caused brain oedema and
microbleeding in some patients.
Phase II: decreases in total tau and phosphorylated tau in
CSF. No clear changes in CSF Aβ.
Two Phase III trials, 2012 : no clinical benefit in mild-tomoderate AD compared to placebo. Development scaled
back.
Two Phase III trials, 2012: dose-dependent increase in
unbound cerebrospinal fluid Aβ1–42, but no change in
cognitive decline or functional ability in mild and moderate
AD. Secondary analysis suggested it slowed cognitive
decline in patients with mild AD.
(http://www.hcplive.com/conferences/aan-2013/Efficacyand- Safety-of-Intravenously-Administered-Solanezumabin-the- Treatment-of-Patients-with-Mild-to-ModerateAlzheimers-Disease)
Phase II results, Russian trial 2008: improvements in
cognitive, global, daily function and behavior endpoints.
Phase III, 2012: patients with mild-to-moderate AD
showed no improvement in cognition or functional ability.

Abbreviations: Aβ, amyloid-β; CSF, cerebrospinal fluid; PDAPP mice, (Tg) transgenic mice overexpressing mutant human amyloid
precursor protein V717F.
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